Paul Boulware, MD
Psychiatry · Phoenix, AZNPI 1609912146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 412 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 412 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$692
- Indivior Inc.$578
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$558
- Otsuka America Pharmaceutical, Inc.$536
- Lundbeck LLC$496
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,57399%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,146 |
| Alkermes, Inc. | 28 | $692 |
| Indivior Inc. | 27 | $578 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $558 |
| Otsuka America Pharmaceutical, Inc. | 28 | $536 |
| Lundbeck LLC | 41 | $496 |
| Johnson & Johnson | 22 | $423 |
| Neurocrine Biosciences, Inc. | 19 | $332 |
| Tris Pharma Inc | 16 | $285 |
| Braeburn Inc. | 16 | $251 |
| Axsome Therapeutics, Inc. | 9 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $220 |
| Vanda Pharmaceuticals Inc. | 7 | $196 |
| Supernus Pharmaceuticals, Inc. | 7 | $122 |
| Corium, LLC | 14 | $121 |
| Almatica Pharma LLC | 5 | $104 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Orexo US, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $21 |
| Tempus AI, Inc | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Neos Therapeutics, LP | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $13 |
How this compares
$6,644 in reported general payments places this provider in the 90th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 253 | $285,902 |
| IngrezzaValbenazine Tosylate | 24 | $199,920 |
| VraylarCariprazine Hcl | 61 | $87,572 |
| Wellbutrin XlBupropion Hcl | 12 | $68,410 |
| CaplytaLumateperone Tosylate | 58 | $41,433 |
| RexultiBrexpiprazole | 12 | $27,902 |
| AuvelityDextromethorphan Hbr/Bupropion | 55 | $19,583 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 90 | $14,739 |
| AmbienZolpidem Tartrate | 22 | $14,002 |
| Adderall XrDextroamphetamine/Amphetamine | 29 | $9,188 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,136 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $6,839 |
| Bupropion XlBupropion Hcl | 141 | $5,073 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 117 | $4,448 |
| Lisdexamfetamine Dimesylate | 14 | $3,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $423 | $285,902253 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $332 | $199,92024 claims |
| AbbVieVraylar | $1,146 | $87,57261 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $558 | $41,43358 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $536 | $27,90212 claims |
| Axsome Therapeutics, Inc.Auvelity | $228 | $19,58355 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $220 | $9,13623 claims |
| Indivior Inc.Suboxone | $578 | $6,83912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Eric ReimanPhoenix$157K
- Padma AkingPhoenix$44K
- Ahmed ElmaadawiPhoenix$32K
- Amnon KahanePhoenix$18K
- Aaron ClayPhoenix$14K
- Joel ParkerPhoenix$11K
- Ivan EngelPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.